Listed

Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2016

Filed with the SEC on May 9, 2016 and accepted by EDGAR at May 9, 2016, 16:32 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-01-01 to 2016-03-31$679.0kus-gaap:Revenues
Cost of revenue3 months2016-01-01 to 2016-03-31$523.0kus-gaap:CostOfRevenue
Gross profit3 months2016-01-01 to 2016-03-31$156.0kus-gaap:GrossProfit
Research and development3 months2016-01-01 to 2016-03-31$7.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2016-01-01 to 2016-03-31$2.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-01-01 to 2016-03-31−$7.9mus-gaap:OperatingIncomeLoss
Net income3 months2016-01-01 to 2016-03-31−$8.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-01-01 to 2016-03-31−$0.09us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2016-01-01 to 2016-03-31−$9.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2016-01-01 to 2016-03-31$251.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-03-31$66.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-03-31$76.3mus-gaap:AssetsCurrent
Total assetsAt period end2016-03-31$87.3mus-gaap:Assets
Current liabilitiesAt period end2016-03-31$9.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-03-31$84.7mus-gaap:Liabilities
Shareholders' equityAt period end2016-03-31$2.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-16-099933. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.